Published on 10/12/2025

Screening vs Targeted Analysis: When Each Approach Is Defensible

Introduction to Extractables and Leachables (E&L) in Pharmaceutical Packaging

The evaluation of extractables and leachables (E&L) is critical in the pharmaceutical industry to ensure product safety and efficacy. Extractables refer to the substances that can be extracted from packaging materials when subjected to extreme conditions, while leachables are those that migrate into the drug product under normal conditions. Both terms are crucial in the context of container closure integrity (CCI) and validation of single-use systems.

The focus of this tutorial is to differentiate between screening and targeted analyses, two pivotal approaches in E&L assessment, and how they integrate into the broader regulatory framework, specifically under the guidelines set forth by FDA, EMA, and MHRA. Understanding when to utilize each can significantly impact the outcomes of E&L risk assessment and compliance with standards such as the analytical evaluation threshold (AET) and dose-based threshold (DBT).

Understanding the Regulatory Landscape

It is imperative for pharmaceutical professionals to remain aligned with current regulatory guidelines. Relevant frameworks include the EU GMP Annex 1, which emphasizes the importance of E&L evaluations, and the PQRI guideline, which provides insights on best practices for polymeric materials in drug manufacturing. Understanding these regulations aids in determining the right approach—screening or targeted analysis—necessary for compliance.

Both approaches are defensible within their contexts, but their application depends on several factors, such as the nature of the drug product, the intended use of the packaging, and the overall risk profile associated with E&L. This guide outlines a systematic approach to selecting an appropriate E&L testing strategy, focusing particularly on the AET and DBT calculations.

Step 1: Identify the Need for E&L Analysis

The first step in the E&L testing process is to identify the need for analysis, which can derive from regulatory mandates, product specifications, or risk assessments. This evaluation process enables professionals to clarify the scope of their E&L assessment, ensuring that both screening and targeted analyses are relevant to the product in question.

• New Product Development: When developing new drug products, it is critical to establish the potential risk of leachables from the packaging materials used.
• Regulatory Compliance: Regulatory agencies may require E&L data to authorize new drug applications or approvals.
• Changes in Production: Any change in the packaging system, manufacturing process, or materials may necessitate a re-evaluation of E&L profiles.

Step 2: Understand the Screening vs. Targeted Analysis Approaches

Screening analysis is a preliminary testing method designed to assess a broad range of potential extractables and leachables using generic solvents and aggressive conditions. It aims to identify contaminants that may not be present during normal use conditions. Conversely, targeted analysis focuses on specific compounds that have been identified through the screening process or are known to be inherently problematic based on previous studies or historical data from similar products.

Selection of either method depends on various criteria, including:

• Risk Profile: High-risk products may require a targeted approach to address specific leachables that present a known regulatory concern.
• Intent of Use: For a product that may involve compromised integrity, a more comprehensive screening analysis might identify potential failure points.
• Causal Factors: Previous analytical data can help inform the choice of method, especially if certain contaminants have been demonstrated to pose a risk.

Step 3: Conducting the E&L Risk Assessment

The E&L risk assessment process is integral to making informed choices regarding the testing approach. A systematic risk framework includes several components:

1. Define the Scope: Identify the specific products and materials that require assessment.
2. Determine AET/DBT: Calculate the AET and DBT, critical components for understanding the acceptable limits of detected leachables under defined conditions.
3. Evaluate Container Closure: Particularly relevant for drug products requiring intact and reliable CCI, assess the integrity of the primary packaging throughout the product’s shelf life.
4. Data Collection: Gather all relevant historical data, prior E&L test results, and risk categories outlined by regulatory agencies.
5. Apply Regulatory Guidelines: Ensure compliance with applicable guidelines (USP, FDA, EMA) in the evaluation process.

Step 4: Application of Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The AET and DBT concepts play a critical role in determining the acceptable levels of leachables in drug products. AET is applied to evaluate extractables that may be present in amounts below analytical detection limits, while DBT is typically used for toxicologically derived thresholds based on the maximum daily dose of the drug product.

The calculation and application of these thresholds are essential for appropriate risk management:

• AET Calculation: Generally derived from toxicological data, the AET serves as a lower threshold value, identifying leachables that necessitate further testing and analysis.
• DBT Consideration: The DBT allows for toxicological evaluation of leachables based on patient exposure. It is crucial for pharmacologically active compounds to adhere to established safety margins.

Both thresholds must align with regulatory expectations, which include adherence to established standards such as those outlined by the FDA process validation guidelines. Testing results must be well documented and justified during regulatory submissions.

Step 5: Running Screening and Targeted Analyses

After establishing the foundational aspects of the analysis, the next step involves executing both screening and targeted methods:

Screening Analysis

This analysis typically employs a generalized multi-solvent extraction strategy under elevated conditions. The screening method will often utilize:

• A combination of solvents such as water, ethanol, and organic solvents based on polarity.
• Extended extraction time and elevated temperature to ensure comprehensive extraction.
• Broad-spectrum analytical techniques (such as LC-MS or GC-MS) to encompass a wide range of potential leachables.

The results from screening should identify and quantify a range of potential E&L’s, providing valuable insights into any possible contaminants.

Targeted Analysis

Following the screening phase, targeted analysis is performed based on the results obtained. This includes:

• Verification of specific compounds using lower detection limits focused on those highlighted during screening.
• Refinement of the analytical method (e.g., by employing more selective detectors) to increase sensitivity for specific analytes.
• In-depth toxicological assessment for any detected leachables that exceed established AET or DBT values.

Step 6: Data Interpretation and Reporting for Compliance

Once all analyses are performed, the data must be interpreted in the context of regulatory compliance, product safety, and potential health risks. Key considerations include:

• Reviewing against the AET and DBT thresholds to identify any leachables that exceed acceptable levels and require action.
• Documenting methodologies, findings, and deviations to support compliance during regulatory submissions.
• Ensuring comprehensive reporting aligning with industry regulations, including identified corrective actions for any non-compliances.

Conclusion and Best Practices for E&L Evaluation

In summary, the choice between screening and targeted analyses must be guided by scientific rationale, risk assessment, and regulatory expectations. Staying informed of industry standards and regulatory changes is crucial to ensuring compliance while safeguarding product integrity and patient safety.

Best practices involve:

• Maintaining ongoing training for personnel involved in E&L evaluations.
• Regularly reviewing and updating standard operating procedures (SOPs) to reflect current regulatory guidance.
• Utilizing a risk-based approach when determining testing strategies, ensuring alignment with AET and DBT considerations.

By diligently applying these protocols and maintaining the highest standards of compliance, pharmaceutical professionals can effectively navigate the complexities of E&L assessments to uphold product safety and integrity.